Our meta-analysis evaluated the efficacy of subcutaneous tirzepatide (5 mg, 10 mg and 15 mg once weekly) with placebo or GLP-1 RAs in people with obesity or overweight. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.